Aeterna Zentaris and Ceapro Merger Approved by Securityholders at Special Meetings
12 mars 2024 14h10 HE
|
Aeterna Zentaris Inc
TORONTO and EDMONTON, March 12, 2024 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna”) and Ceapro Inc. (TSX-V: CZO; OTCQX: CRPOF) (“Ceapro”) are pleased to announce...
Aeterna Zentaris Provides Business Outlook and Outlines Pipeline Priorities
26 janv. 2022 08h05 HE
|
Aeterna Zentaris Inc
– Company advancing diversified portfolio focused on areas of significant unmet medical need– Supported by solid financial position with cash to fund operations beyond 2023 TORONTO,...
Global Human Growth Hormone Market to reach $9.21 billion by 2030: Allied Market Research
11 oct. 2021 04h12 HE
|
Allied Market Research
Portland, OR, Oct. 11, 2021 (GLOBE NEWSWIRE) -- According to the report published by Allied Market Research, the global Human Growth Hormone Market generated $3.86 billion in 2020, and is projected...
Aeterna Zentaris Commences Pivotal Phase 3 DETECT-Trial for the Diagnosis of Childhood-Onset Growth Hormone Deficiency
13 mai 2021 08h05 HE
|
Aeterna Zentaris Inc
– Safety and efficacy study for macimorelin initiated as agreed with U.S. FDA and the European Medicines Agency ("EMA") in the Company's Pediatric Investigation Plan ("PIP") – Patient enrollment on...
Growth Hormone Market revenue to cross USD 5.3 Bn by 2027: Global Market Insights Inc.
29 avr. 2021 07h00 HE
|
Global Market Insights, Inc
Selbyville, Delaware, April 29, 2021 (GLOBE NEWSWIRE) -- According to latest report “Growth Hormone Market by Product (Powder, Solvent), Application (Growth Hormone Deficiency, Idiopathic Short...
Aeterna Zentaris Regains Compliance with Nasdaq Minimum Bid Price Requirement
22 mars 2021 16h05 HE
|
Aeterna Zentaris Inc
CHARLESTON, S.C., March 22, 2021 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or the “Company”), a specialty biopharmaceutical company commercializing and...
Aeterna Zentaris Announced Presentation of Positive Results from First Pediatric Study of Macimorelin at the 22nd European Congress of Endocrinology
08 sept. 2020 08h05 HE
|
Aeterna Zentaris Inc
- PK and PD profiles of macimorelin for pediatric use were within the expected range and comparable to results observed in adults - - Data from this study support the choice of 1.0 mg/kg dose of...
Ascendis Pharma Announces Once-weekly TransCon™ Growth Hormone Demonstrated Superiority on Primary Endpoint Compared to a Daily Growth Hormone in Phase 3 heiGHt Trial for Pediatric Growth Hormone Deficiency
04 mars 2019 06h30 HE
|
Ascendis Pharma A/S
- TransCon hGH demonstrated comparable safety and tolerability to a daily hGH - - Potential once-weekly treatment option to overcome long-standing challenges with administration of daily hGH - -...
Ascendis Pharma A/S Introduces Vision 3x3: A Strategic Roadmap Through 2025 to Achieve Sustainable Growth Using Multiple Approaches
07 janv. 2019 09h00 HE
|
Ascendis Pharma A/S
COPENHAGEN, Denmark, Jan. 07, 2019 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative TransCon™ technologies to address significant...
Ascendis Pharma A/S Announces Support for Children’s Growth Awareness Week and Day 2018
17 sept. 2018 16h10 HE
|
Ascendis Pharma A/S
COPENHAGEN, Denmark, Sept. 17, 2018 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative TransCon™ technology to address significant unmet...